Famewave Ltd.

Tel Aviv University

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Ccam Biotherapeutics Ltd.

Jacob Schachter

Gal Markel

Rona Ortenberg

Yair Sapir

Ilana Mandel

Timothy David Jones

Tehila Ben-Moshe

Robert George E Holgate

Francis Joseph Carr

Tehila Ben Moshe

Eyal Greenberg

Francis J Carr

Noam Shomron

Liat Edry

Robert George Holgate

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

Polynucleotides encoding humanized antibodies against CEACAM1

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

A method for diagnosing a cancer characterized by over expression of CEACAM1 using an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.

Anti CEACAM1 antibodies and methods of using same

The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

Microrna patterns for the diagnosis, prognosis and treatment of melanoma

MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma

Growing community of inventors

Givatayim, Israel

Jacob Schachter